Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$STSS
Medical/Dental Instruments
Health Care
Get the next $STSS alert in real time by email
false 0001737995 0001737995 2025-01-28 2025-01-28 0001737995 STSS:CommonStock0.0001ParValueMember 2025-01-28 2025-01-28 0001737995 STSS:CommonStockPurchaseWarrantsMember 2025-01-28 2025-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): January 28, 2025

 

Sharps Technology, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada

(State or Other Jurisdiction of Incorporation)

 

001-41355   82-3751728

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

105 Maxess Road, Melville, New York 11747

(Address of Principal Executive Offices)

 

(631) 574 -4436

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   STSS   NASDAQ Capital Market
Common Stock Purchase Warrants   STSSW   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On January 28, 2025, pursuant to the registration statement on Form S-1, as amended (File No. 333-284237) (the “Registration Statement”), Sharps Technology, Inc., a Nevada corporation (the “Company”) consummated a public offering (the “Offering”) of an aggregate of (i) 14,285,714 units (the “Units) at a public offering price per Unit of $1.40 with each Unit consisting of one share of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), one Series A Warrant (the “Series A Warrant”) to purchase one share of Common Stock at an exercise price of $1.750 per share and one Series B Warrant to purchase one share of Common Stock at an exercise price of $1.750 (the “Series B Warrant” and, together with Series A Warrant, the “Warrants”); and (ii) 10,833,500 pre-funded units (the “Pre-Funded Units”) at a public offering price of $1.3999 per Pre-Funded Unit, with each Pre-Funded Unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) exercisable for one share of Common Stock at an exercise price of $0.0001 per share, one Series A Warrant and one Series B Warrant. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

 

The Series A Warrants will be exercisable from issuance and will expire five (5) years after the Warrant Stockholder Approval Date and the Series B Warrants will be exercisable from issuance and will expire two and one-half (2.5) years after the Warrant Stockholder Approval Date (the “Warrant Stockholder Approval Date”).

 

The offering closed on January 29, 2025. The net proceeds to the Company from the Offering were approximately $18,200,000, after deducting underwriter fees and the payment of other estimated offering expenses associated with the offering that are payable by the Company. The Company intends to use the net proceeds from the offering for repayment of debt, working capital and other general corporate purposes.

 

Aegis Capital Corp. served as the underwriter in the offering, pursuant to the terms of an Underwriting Agreement, and received seven percent (7%) of the gross proceeds of the offering, a one percent (1%) non-accountable allowance and reimbursement of the legal fees of its counsel.

 

The Units and Pre-Funded Units were offered by the Company pursuant to a Registration Statement on Form S-1, as amended (File No. 333-284237), which was originally filed with the Securities and Exchange Commission (“the SEC”) on January 10, 2025, and declared effective by the SEC on January 27, 2025. The final prospectus relating to the offering was filed with the SEC on January 29, 2025.

 

The foregoing summary of the terms of the Pre-Funded Warrant, Series A Warrant, Series B Warrant, and the Underwriting Agreement are subject to, and qualified in their entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 4.1, 4.2, 4.3, and 10.1 respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.   Description
4.1   Form of Pre-Funded Warrant
4.2   Form of Series A Warrant
4.3   Form of Series B Warrant
10.1   Underwriting Agreement between the Company and Aegis Capital Corp., dated January 28, 2025
99.1   Press Release issued by the Company on January 28, 2025
99.2   Press Release issued by the Company on January 29, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 30, 2025

 

SHARPS TECHNOLOGY, INC.  
   
/s/ Robert Hayes  
Robert Hayes  
Chief Executive Officer  

 

 

 

Get the next $STSS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STSS

DatePrice TargetRatingAnalyst
More analyst ratings

$STSS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering

    NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ:STSS) (the "Company"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering closed on January 29, 2025. The offering consisted of 14,285,714 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant, (ii) one (1) Series A Register

    $STSS
    Medical/Dental Instruments
    Health Care
  • Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering

    NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ:STSS) (the "Company"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering consists of 14,285,714 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant, (ii) one (1) Series A Registered Common Warrant to purchase one (1) sha

    $STSS
    Medical/Dental Instruments
    Health Care
  • Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue

    Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery scheduleInitial production and commercial deliveries to begin in Q1 2025     Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Exe

    $STSS
    Medical/Dental Instruments
    Health Care

$STSS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$STSS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$STSS
SEC Filings

See more

$STSS
Leadership Updates

Live Leadership Updates

See more
  • Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

    NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

    $STSS
    Medical/Dental Instruments
    Health Care
  • Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

    Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

    $STSS
    Medical/Dental Instruments
    Health Care
  • Sharps Technology Appoints Justin Page as Vice President of Technical Operations

    NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

    $STSS
    Medical/Dental Instruments
    Health Care

$STSS
Financials

Live finance-specific insights

See more
  • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

    $SNGX
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

    $AREC
    $RVPH
    $STSS
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

$STSS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more